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Abstract
A large proportion of patients with chronic kidney disease (CKD) are vitamin D deficient (plasma 25-hydroxyvitamin D 
(25(OH)D) < 25 or 30 nmol/L per UK and US population guidelines) and this contributes to the development of CKD–mineral 
bone disease (CKD–MBD). Gaps in the evidence-base for the management of vitamin D status in relation to CKD–MBD are 
hindering the formulation of comprehensive guidelines. We conducted a systemic review of 22 RCTs with different forms of 
vitamin D or analogues with CKD–MBD related outcomes and meta-analyses for parathyroid hormone (PTH). We provide a 
comprehensive overview of current guidelines for the management of vitamin D status for pre-dialysis CKD patients. Vitamin 
D supplementation had an inconsistent effect on PTH concentrations and meta-analysis showed non- significant reduction 
(P = 0.08) whereas calcifediol, calcitriol and paricalcitol consistently reduced PTH. An increase in Fibroblast Growth Factor 
23 (FGF23) with analogue administration was found in all 3 studies reporting FGF23, but was unaltered in 4 studies with 
vitamin D or calcifediol. Few RCTS reported markers of bone metabolism and variations in the range of markers prevented 
direct comparisons. Guidelines for CKD stages G1–G3a follow general population recommendations. For the correction of 
deficiency general or CKD-specific patient guidelines provide recommendations. Calcitriol or analogues administration is 
restricted to stages G3b–G5 and depends on patient characteristics. In conclusion, the effect of vitamin D supplementation 
in CKD patients was inconsistent between studies. Calcifediol and analogues consistently suppressed PTH, but the increase 
in FGF23 with calcitriol analogues warrants caution.
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Introduction
Chronic kidney disease (CKD) is an international public 
health problem affecting 5–10% of the world population [1]. 
It is defined on the basis of an estimated glomerular filtra-
tion rate (eGFR) and values less than 60 mL/min/1.73  m2 
are considered the threshold for CKD [2–4]. Many are 
undiagnosed and asymptomatic. Only in the UK there are 
approximately 1 million undiagnosed CKD patients [5]. 
CKD results in changes in vitamin D metabolism, calcium 
and phosphate homeostasis and bone metabolism [6, 7]. This 
leads to CKD metabolic bone disease (CKD–MBD) [7].
The prevalence of vitamin D deficiency is higher in CKD 
patients than in the general population [6]. Vitamin D status 
is most commonly assessed on the basis of the plasma con-
centration of 25-hydroxyvitamin D (25(OH)D or calcidiol). 
Vitamin D deficiency thresholds for population health are 
defined as 25(OH)D serum levels < 25 or 30 nmol/L per UK 
and US guidelines [8, 9]. Thresholds for patient management 
are mostly set higher.
Many factors contribute to the high prevalence of vita-
min D deficiency in CKD patients. Dependent on the stage 
of CKD and presence or severity of secondary hyperpar-
athyroidism (SHPT), supplementation with vitamin D, ana-
logues or its active form is recommended. Guidelines for 
management of CKD patients combine those for the general 
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population, general patient management and guidelines spe-
cific for CKD patients. This requires detailed knowledge of 
recommendations on vitamin D for the protection of pop-
ulation health, patient care and the specific guidelines to 
correct vitamin D deficiency. Due to differences in recom-
mendations between advisory bodies, this is perceived to 
be confusing.
There are still many gaps in the evidence base for the 
management of vitamin D status in relation to CKD–MBD, 
including the role of vitamin D in the aetiology and man-
agement of SHPT, altered bone metabolism, bone density 
and integrity and fracture risk. These include the altered 
dose–response to vitamin D supplementation and the 
response in parathyroid hormone (PTH) in these patients. 
The optimal concentration ranges of PTH and 25(OH)D for 
the management and prevention of CKD–MBD are also not 
well established for each stage of CKD.
Here we briefly summarise alterations in vitamin D 
metabolism and bone metabolism with CKD and gaps in 
the evidence base. We present the findings of a systematic 
review of recent RCTs with different forms of vitamin D in 
CKD patients with a focus on CKD–MBD related outcomes. 
Meta-analyses were conducted to provide estimates of the 
effectiveness of supplementation on plasma PTH concentra-
tions. Secondly, we provide a comprehensive review of the 
available guidelines for adult pre-dialysis renal patients for 
the management of vitamin D status and SHPT. We gener-
ated a road map, tabulating guidelines from different organi-
zations on the form and dosages of vitamin D recommended 
to prevent or correct vitamin D deficiency and target values 
of plasma 25(OH)D concentrations, according to the differ-
ent stages of CKD. Population guidelines are summarized 
as part of this road map where they apply to CKD patients.
The Physiology of Altered Vitamin D and Bone 
Metabolism with CKD
The alterations in vitamin D metabolism [6], calcium and 
phosphate homeostasis and bone metabolism [6] with CKD 
is multifactorial and associated with CKD–MBD [7].
A high proportion, 70–80%, of CKD patients have a 
plasma 25(OH)D concentration below 50 nmol/L [6] and 
the majority well below the concentration recommended for 
patients with renal impairment (> 75 nmol/L), if not treated. 
Many factors contribute to the high prevalence of vitamin 
D deficiency in CKD patients and changes in vitamin D 
metabolism occur at several levels (Fig. 3).
Supply is decreased as a result of lower cutaneous vita-
min D production due to skin hyperpigmentation, age-
ing, sun avoidance and dietary restrictions [10]. Losses 
are increased with proteinuria, when vitamin D binding 
protein and albumin and vitamin D metabolites bound to 
these proteins are lost in urine [10]. Hepatic conversion 
of vitamin D into 25(OH)D is reported to be suppressed 
in CKD patients [11–13]. Accordingly, the dose–response 
appears to be lower than in healthy individuals, although 
this is poorly characterized.
With the loss of functional renal tissue the capacity 
to convert 25(OH)D to 1,25(OH)2D (1,25 dihydroxy 
vitamin D or calcitriol) is reduced leading to a decline 
in plasma 1,25(OH)2D [11]. Also the renal capacity to 
internalise 25(OH)D may be impacted, reducing its avail-
ability of 25(OH)D. In healthy people, plasma 25(OH)D 
concentrations between 15 and 40 nmol/L are thought to 
be required to ensure there is no substrate limitation for 
renal 1,25(OH)2D production [14]. In people with CKD, 
higher concentrations may be required.
Plasma PTH increases in response to impaired 
1,25(OH)2D production and calcium malabsorption in 
combination with increased resistance of the kidneys and 
bone to PTH, due to a downregulation of PTH receptor 
type 1 (PTHR1) [15]. An increase in plasma phosphate and 
Fibroblast Growth Factor-23 (FGF23) further stimulate 
PTH secretion.
The plasma concentration of FGF23 increases in early 
stages of CKD, before an increase in plasma phosphate is 
detectable [16]. FGF23 is a phosphaturic hormone which is 
predominantly produced by osteocytes and acts in the kid-
neys to increase phosphate excretion [16]. It requires the 
co-factor αKLOTHO, the expression of which decreases 
with ageing and renal impairment, thereby decreasing 
FGF23 receptor activation. FGF23 also has other func-
tions. FGF23 stimulates the catabolism of both 25(OH)D 
and 1,25(OH)2D. FGF23 also downregulates the expres-
sion of 1a(OH)ase, suppressing the production of renal 
1,25(OH)2D. Further, FGF23 can stimulate PTH secretion 
[16], although the mechanism of this FGF23-PTH interac-
tion is not well understood. An increased plasma FGF23 
concentration is associated with soft tissue calcification, 
increased risks of cardiovascular disease (CVD) and the 
promotion of CKD–MBD [16].
CKD–MBD has a heterogeneous phenotype due to the 
involvement of several underlying mechanisms, in which 
SHPT plays an important role [35]. CKD–MBD can either 
be characterised by an increase or a decrease in bone 
turnover, but may also be normal. An increase can lead 
to osteomalacia, which is characterized by the excessive 
presence of undermineralised bone tissue and osteoporosis 
defined as a low bone mineral density (Z-score − 2.5 SD) 
and loss of bone integrity. A decrease in bone remodel-
ling leads to adynamic bone disease increasing fracture 
risk [1]. CKD–MBD is therefore generally characterized 
by a decrease of bone integrity, increased fracture risk 
and calcification of soft tissues [7] and alterations in bone 
turnover markers [1]. In the management of SHPT and 
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CKD–MBD, maintenance of a sufficient vitamin D status 
is recognized as an important target.
Clinical Trials of Vitamin D in CKD Patients and Gaps 
in the Evidence‑Base
There are gaps in the evidence base for the management 
of vitamin D status in relation to CKD–MBD, i.e. SHPT, 
altered bone metabolism, bone density and integrity and 
fracture risk. These include the dose- response to vitamin 
D supplementation and the response in PTH. The optimal 
concentration ranges of PTH and 25(OH)D for the manage-
ment and prevention of CKD–MBD are not well established 
for each stage of CKD. This is reflected in the guidelines for 
the management of vitamin D status in CKD–MBD.
The limited number of randomized controlled trials 
reporting the effects of treatment with vitamin D or its ana-
logues on CKD–MBD related outcomes provided conflict-
ing results [18–31]. Several studies also reported the effect 
of supplementation on renal function and proteinuria [32] 
and markers of endothelial and cardiovascular function and 
inflammation [33, 34]. The effects were shown to depend on 
the stage of the disease [35, 36]. Adverse treatment effects 
were reported, particularly with active vitamin D and ana-
logues and includes hypercalcemia [37, 38], adynamic bone 
disease and increased FGF23 levels [39].
Systematic Review and Meta‑analyses 
of Randomised Controlled Trials
In this systematic review we aimed to summarize the find-
ings of the most recent randomized controlled trials report-
ing the effects of vitamin D or its analogues, conducted with 
pre-dialysis CKD patients and that report 25(OH)D, PTH, 
markers of calcium and phosphate and/or bone metabolism. 
Where provided, we also summarized adverse effects and 
other outcomes that may be relevant for vitamin D metab-
olism (e.g. proteinuria) or the effects of interventions on 
markers of vascular health. Findings are grouped according 
to form of vitamin D given, preceded by a short description 
of their characteristics. Meta-analyses were conducted to 
provide estimates of the effectiveness of supplementation on 
plasma PTH concentrations. There were insufficient studies 
and data to conduct meaningful meta-analyses for markers 
of bone turnover or FGF23.
Methods
Search Strategy
We searched for published studies indexed in MEDLINE, 
EBSCO, Science direct and PubMed from inception of 2003, 
the year that NKF KDOQI guidelines were published, to 
October of 2020. Search terms used: vitamin D, oral vita-
min D, vitamin D supplementation, vitamin D analogues, 
paricalcitol, calcifediol, calciferol, ergocalciferol, chronic 
kidney/renal disease, renal/kidney impairment, impaired 
kidney/renal failure, RCT, randomised controlled trials. 
Search terms for outcomes were not used in order not to 
limit search results. Instead, papers were selected on basis of 
relevant outcomes. English was applied as a language limi-
tation. Only full text published manuscripts were included. 
References were hand searched for additional publications.
Inclusion Criteria
The detailed process of study selection presented on Fig. 1. 
Only randomized controlled trials (RCT) were included that 
used any type of vitamin D in non-dialysis CKD patients 
(> 18 years old) and studies at any stage of the disease were 
considered. Studies were included if placebo controlled, 
compared 2 or more treatments or were randomized cross-
over studies. Studies had to include a definition of dosage 
and duration of the vitamin D administered and outcomes 
related to CKD–MBD. This systematic search provided 22 
RCTs (Table 1).
Quality Assessment
The 22 studies were assessed for their methodological qual-
ity using the Van Tulder et al. criteria list [40] by two inde-
pendent investigators (Table 1). High quality studies were 
defined with score ≥ 8 and low quality with score ≤ 7.18. 
Scores are provided in Table 1.
Meta‑analyses
Plasma PTH concentrations were converted into uniform 
units (pg/ml). Random effect models were used for all meta-
analyses because of differences in form, dosages, duration 
and study population. Heterogeneity was assessed with the 
I2 test. Separate analyses were conducted for studies using 
the precursor of 1,25(OH)2D (i.e. vitamin D or 25(OH)D) 
and those with 1,25(OH)2D or analogues. The decision to 
separate these studies was based on high heterogeneity  (Chi2 
P = 0.001: I2 = 65%) resulting when both forms were ana-
lyzed together and on biological plausibility. Analyses used 
the reported mean and standard deviations or confidence 
intervals, either between treatment groups and/or placebo 
as appropriate. Not all studies reported sufficient detail for 
inclusion. Some studies could not be included because of the 
type of data reported (e.g. as % difference between groups or 
geometric mean or median values for non-normally distrib-
uted data). In view of the limited number of placebo–con-
trolled studies, baseline data were used as comparator for 
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some studies. Four studies reported baseline and post-pla-
cebo treatment data and none of these individual studies 
reported a significant change in PTH and differences were 
small. This was confirmed by meta-analysis showing a non-
significant change (results not shown).
Meta-analyses were performed using RevMan (version 
5.4; non-Cochrane Collaboration). A P-value of ≤ 0.05 was 
considered significant.
Results
RCTs with Vitamin D Supplementation
Vitamin D is the inactive precursor of 1,25(OH)2D and exists 
in two forms, vitamin  D3 (cholecalciferol) and  D2 (ergocal-
ciferol). Vitamin D is the most commonly used form for the 
prevention and treatment of deficiency in both the general 
population and patient groups. Vitamin  D3 supplementation 
leads to a somewhat longer sustained increase of 25(OH)
D, but otherwise the metabolism of  D3 and  D2 is identical.
Nine of the RCTs included in this systematic review used 
vitamin  D3 (six studies) [25, 41–45] or  D2 (three studies) [21, 
29, 46] supplementation (Table 2). All studies has a small 
sample size (n < 100). In some of these studies the group 
that received Vitamin D served as the reference group. They 
were all conducted with CKD patients stages 3–4. The doses 
varied from 2000 to 4000 IU daily or 40,000–50,000 IU 
weekly and the duration was between 1 and 12 months. All 
nine studies found a significant increase in plasma 25(OH)D 
concentrations. Four [41–43, 46] of these studies observed 
a significant reduction of PTH, whilst in the remaining five, 
no significant change of PTH in response to the vitamin 
D supplementation was found [25, 29, 44, 45]. The small 
sample sizes, differences in dosages and duration of sup-
plementation may explain these inconsistent results; higher 
doses show to be more effective in suppressing PTH. Only 
five of these studies provided sufficient detail for inclusion in 
meta-analysis, which showed a non-statistically significant 
Fig. 1  Flow chart of systematic 
search and literature selection. 
Adjusted from PRISMA proto-
col 2019
Records idenfied through 
database searching
(n=204)
Addional records idenfied 
through other sources
(n=15)




Records excluded: no 
relevant outcomes
(n=145)
Full-text arcles assessed 
for eligibility
(n=37)
Full-text screened arcles 
excluded: not meeng 
inclusion criteria
(n=15)
Final arcles included in the 
qualitave synthesis
(n=22)
Arcles included in meta-
analyses
(n=9)
Arcles excluded from 
meta-analyses due to the 
form of results reported
(n=13)
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decrease in PTH of 18 pg/mL (CI − 37 to 2; P = 0.8 see 
Fig. 2a). When also two studies with calcifediol were consid-
ered, the effect on PTH was highly significant (P < 0.0001), 
but heterogeneity was substantial (I2 = 60%) (not shown).
Only three of the studies [25, 44, 45] measured changes 
in 1,25(OH)2D, with two showing a significant increase with 
supplementation. Most of the studies reporting no effect of 
the supplementation on PTH, also noted no effect on calcium 
and phosphate concentrations. Only one study measured 
FGF23 and found no change. Bone turnover markers were 
only reported in two studies. Alkaline Phosphatase (ALP), 
C-terminal telopeptide (CTx) and Tartrate-resistant acid 
phosphatase 5b (TRAP5b) were shown not to change with 
supplementation. One study reported a significant improve-
ment on the endothelium dependent microcirculatory vaso-
dilation and other markers of vascular function.
RCTs with Calcifediol Supplementation
In recent years, preparations of the 25 hydroxylated form 
of vitamin D, i.e. 25(OH)D or calcifediol were developed 
for oral administration. There are three forms; calcifediol 
and the extended release (ER) formula, provided as capsules 
and the immediate release (IR), provided as a liquid or cap-
sule. The pharmacokinetic profile differs from the parent 
compound vitamin D. Intestinal absorption of 25(OH)D 
is known to be more efficient and is not dependent on fat 
absorption, the increase in plasma 25(OH)D is more rapid 
and the dose–response higher than that of the parent com-
pound. The IR calcifediol formulation was approved in 
the USA in 1980 for treatment of CKD–MBD in dialysis 
patients [47]. However, it was withdrawn from the market in 
2002, since it failed to show meaningful reduction of PTH 
(≥ 30%) in patients with CKD G3–4. IR calcifediol is still 
available in Europe and licensed for use in various condi-
tions including vitamin D deficiency rickets, renal osteopa-
thy and hypocalcaemia [47]. ER formulations of 25(OH)D 
are only available in the USA at the moment [47]. In 2016 
ER calcifediol was approved in the USA to treat SHPT in 
adult CKD patients G3–4 and vitamin D insufficiency [47]. 
Studies in CKD patients showed that ER calcifediol results 
in a slower increase of 25(OH)D levels, more significant 
suppression of iPTH and less of an increase of 24,25(OH)D 
compared to IR-calcifediol [48].
Three ER calcifediol and one calcifediol study in CKD 
patients (G2–4) published since 2003 were found in our 
Table 1  Quality assessment of the RCTs included in the systematic review according to Tulder et al. [40]
Green: Yes, Red: No, Grey: Unknown. 1. Was the method of randomization adequate? 2. Was the treatment allocation concealed? 3. Were the 
groups similar at baseline regarding the most important prognostic indicators? 4. Was the patient blinded to the intervention? 5. Was the care 
provider blinded to the intervention? 6. Was the outcome assessor blinded to the intervention? 7. Were co-interventions avoided or similar? 8. 
Was the compliance acceptable in all groups? 9. Was the drop−out rate described and acceptable? 10. Was the timing of the outcome assessment 
in all groups similar? 11. Did the analysis include an intention−to−treat analysis?
*Studies included in the meta−analyses
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systematic search [22, 48–50] (Table 1). Dosages and dura-
tions of treatment varied but a significant dose-dependent 
increase in 25(OH)D and a decrease in iPTH was seen after 
oral administration in all studies [22, 48, 49]. A meta-anal-
ysis was not conducted due to limited numbers of studies 
and reported data.
ER calcifediol showed a significant but gradual increase 
of serum 25(OH)D in all three of the studies in contrast 
to the sharp increase with intra-venous administration of 
calcifediol. Intra-venous administration did not significantly 
suppress iPTH but there was an increase in 24,25(OH)2D 
(24,25 dihydroxy vitamin D), a catabolic product of 25(OH)
D. ER calcifediol administration was associated with unal-
tered plasma calcium and phosphate concentrations in all 
studies and FGF23 concentrations in the 2 studies that 
included this measurement.
RCTs: with Calcitriol and Vitamin D Analogues
The active form of vitamin D and its analogues used in the 
treatment of CKD patients include calcitriol and the vita-
min D analogues paricalcitol (19-nor-1,25(OH)2D2) and 
the 1,25(OH)2D precursor alfacalcidol (1a(OH)D3) [51]. 
1,25(OH)2D3 is identical to the endogenous activated form 
of calcifediol (25(OH)D3). Paricalcitol and alfacalcidol, 
the latter of which requires hepatic hydroxylation at the 25 
position, are synthetic analogues of vitamin D [51] and are 
also referred to as vitamin D receptor activators (VDRA). 
VDRAs have been used for the management of SHPT in 
CKD patients for a few decades [52] and show to have reno-
protective properties such as reducing albuminuria, renal 
damage and dysfunction [27, 28, 53]. Paricalcitol suppresses 
PTH secretion whilst it has a lower stimulatory effect on 
intestinal absorption of calcium and phosphate compared to 
1,25(OH)2D [28]. Paricalcitol is also associated with reduc-
tion of cardiovascular events [30], although sufficient studies 
with CKD patients are still lacking.
All twelve studies included CKD patients G3–4, however, 
there were differences between studies in patient charac-
teristics. For example, diabetes, established SHPT, use of 
phosphate binders and proteinuria. The duration of admin-
istration varied from 2 to 48 weeks and the dosages used in 
these studies from 0.25 to 2 μg.
All twelve RCTs showed a significant reduction in plasma 
PTH after administration of paricalcitol or 1,25(OH)2D [19, 
26, 28, 30, 43, 46, 50, 53–58] (Table 1). This was also seen 
in a study that combined 1,25(OH)2D and Vitamin  D2 [21]. 
Meta-analysis of the studies for which sufficient detail was 
available, confirmed this finding but heterogeneity was high 
(Fig. 2b). The effect of paricalcitol on serum 25(OH)D and 
1,25(OH)2D concentrations were inconsistent. Two of the 
studies with paricalcitol [26, 55] reported a reduction of 
1,25(OH)2D after supplementation.
Several studies compared different forms of supplemen-
tation. Kovesdy et al. compared the effects of vitamin  D2 
compared to paricalcitol in vitamin D deficient CKD patient 
with SHPT [46]. In both treatment groups, 25(OH)D sig-
nificantly increased, but only in the paricalcitol group there 
was a significant decrease in PTH. Coyne’s study compared 
the effects of 1,25(OH)2D with paricalcitol [58]. In both 
treatment group there was a significant decrease of PTH. 
However, paricalcitol appeared to be suppress PTH more 
compared to 1,25(OH)2D (− 52% and − 46% PTH reduction, 
respectively). Susantitaphong et al. examined the effect of 
Vitamin  D2 with or without 1,25(OH)2D and found a sup-
pression of PTH only in the combined group [21]. Levin 
et al. [50] compared the effects of oral calcifediol with 
1,25(OH)2D. Both treatment groups had a significant reduc-
tion of PTH, which was larger in the calcifediol group. A 
significant increase in 25(OH)D was shown in the calcifediol 
group, whilst there were no differences between the groups 
in the 1,25(OH)2D concentration. Meta-analysis comparing 
the effects of calcitriol or vitamin D analogues versus the 
administration of the precursor calcidiol or vitamin D on 
PTH, showed no significant difference between these forms. 
However, this analysis was limited to 4 studies for which 
sufficient detail was available and heterogeneity was high 
(Fig. 2c).
Inconsistent results were reported for serum/plasma cal-
cium (four increase; six unchanged) and phosphate (two 
increase; eight unchanged) concentrations after calcitriol of 
analogue administration. Most of the studies reported no 
cases of hypercalcemia. Only one study reported significant 
higher incidence of hypercalcemia in the intervention group 
compared to placebo (22.6% and 0.9%, respectively) [30]. 
An increase in FGF23 after vitamin D analogues (paricalci-
tol) administration was found in all three studies reporting 
this outcome and in two of these studies, also a decrease 
in renal function was reported [26, 28, 55]. An increase in 
FGF23 was not reported in the four studies with Vitamin D 
or calcifediol and one with 1,25(OH)2D. Meta-analysis of 
the FGF23 response to vitamin D or analogue administra-
tion was not conducted due to the low number of studies 
(3) and lack of sufficient information provided (e.g. not all 
manuscripts reported whether intact or c-terminal or intact 
FGF23 was measured).
All four studies that measured either alkaline phosphatase 
(ALP) or bone specific (BALP) after paricalcitol treatment 
reported a decrease in this marker of bone metabolism.
Further outcomes included markers of endothelial and 
cardiovascular function, insulin sensitivity and proteinuria 
and were inconsistent between studies.
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Discussion of Clinical Trials of Vitamin D 
in CKD Patients
As expected, 25(OH)D increased after supplementation, but 
the vitamin D-25(OH)D dose–response appeared to be lower 
than in healthy people. Individual participant data (IPD)-
level meta-analysis to characterize this relationship in CKD 
patients would be helpful to underpin the evidence base of 
vitamin D requirements to prevent and correct vitamin D 
deficiency in CKD patients.
The effect of vitamin D on PTH concentrations was incon-
sistent between individual studies and meta-analysis showed 
a non-significant suppressive effect. Comparing these stud-
ies with a meta-analysis of the PTH response in studies with 
participants not selected on the basis of their renal func-
tion [59, 60], results in CKD patients are less consistent. In 
these meta-analyses which included predominantly partici-
pants without renal impairement, a suppression of PTH was 
found in the majority of studies and meta-analyses found an 
overall reduction in PTH after vitamin D supplementation 
with generally lower dosages of vitamin D supplementation 
compared to dosages used in CKD patients. To address this, 
IPD-level meta-analysis of existing data and a vitamin D 
dose-ranging study in CKD patients with and without SHPT 
is urgently required to characterize the response of PTH to 
vitamin D treatment. This research would also facilitate the 
identification of patient groups that do and do not respond 
with a decrease in PTH to supplementation.
Administration of calcifediol was reported in four stud-
ies and all reported suppression of PTH. This may seem 
surprising since it requires renal activation to 1,25(OH)2D. 
Although it is difficult to compare these results to the admin-
istration of vitamin D, the use of calcifediol to suppress PTH 
in CKD patients holds promise since the risk of over sup-
pression of PTH and hypercalcaemia appears less likely 
compared to calcitriol and paricalcitol.
We found that treatment with calcitriol and paricalcitol 
was associated a consistent and greater suppression of PTH. 
Increased risk of hypercalcaemia was only found in 1 of the 
12 recent studies included in this review. IPD-level meta-
analysis comparing calcifediol with vitamin D and calcife-
diol with calcitriol and its analogues may provide evidence 
of their relative effects. This may aid the incorporation of 
calcifediol in guidelines and provide alternative options for 
patients that might be prescribed calcitriol and paricalcitol.
An increase in FGF23 after treatment with vitamin D ana-
logues was observed in all 3 studies reporting this outcome, 
but was unaltered in 4 studies with Vitamin D or calcifediol. 
This warrants further attention. FGF23 is a phosphaturic 
hormone, reducing phosphate reabsorption from the glo-
merular filtrate through downregulating the available sodium 
phosphate cotransporters [61]. FGF23 also downregulates 
the expression of 1a(OH)ase, suppressing the production 
of renal 1,25(OH)2D and upregulates 24(OH)lase increas-
ing 1,25(OH)2D catabolism [61]. FGF23 is concentration-
dependent and positively correlated with CKD progression, 
heart failure, vascular calcification, left ventricular hyper-
trophy and mortality in CKD patients [62]. These effects are 
partly thought to be caused by increased calcium retention 
caused by increased FGF23 and PTH concentrations [62], 
together with elevated aldosterone concentrations found 
in CKD patients due to activation of the Renin–Angioten-
sin–Aldosterone System (RAAS) [63]. High circulating 
aldosterone may enhance the effect of FGF23 on sodium 
retention in CKD patients and sodium and volume retention 
further contributes to the risk of vascular calcification [62]. 
An increase in both intact and c-terminal FGF23 with vita-
min D supplementation is also reported in a meta-analyses of 
trials with deficient and healthy individuals [64], but so far 
not linked to increased risk of CVD events [64]. It was also 
earlier reported in CKD patients [39]. An increase in FGF23 
may be an undesirable side effect of administration of vita-
min D and its analogues and a better understanding of its 
effects with different forms of vitamin D is required, espe-
cially in CKD patients, in relation to their already increased 
FGF23 concentrations, alterations in vitamin D metabolism 
and increased risk of CVD.
Few RCTs reported the effect of vitamin D on markers 
of bone metabolism and variations in the range of markers 
prevented direct comparisons. However, all four studies that 
measured either ALP or BALP after paricalcitol treatment 
reported a decrease in this marker indicative of increased 
bone turnover in CKD patients.
Several factors may have influenced the overall findings. 
These include form, frequency and dosages of vitamin D 
and its analogues used. The selection of patient population, 
co-morbidities and their use of other medication will have 
influenced the response to supplementation. Further, the 
method used for estimating renal function may have influ-
ence the selection of study participants.
Methods for Estimating Renal Function
All studies included in this review used eGFR as a measure 
to assess kidney function. None applied a direct method. 
Most studies used creatinine based algorithms, and the 
majority the Modification of Diet in Renal Disease 4-vari-
able (MDRD-4) equation, except Zoccali et al. [55] who 
used the Chronic Kidney Disease Epidemiology Collabo-
ration (CKD–EPI) Creatinine-Cystatin C algorithm, that 
incorporates both creatinine and cystatin C. Plasma cre-
atinine is significantly affected by age, nutrition, gender, 
physical activity and muscle mass [65, 66]. Also, Agar-
wal et al. showed that short-term paricalcitol treatment in 
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CKD patients can increase serum creatinine and creatinine 
excretion without altering creatinine clearance [65, 66]. 
MDRD-4 is the most commonly used formula for eGFR in 
medical practice. However, there are differences between 
guidelines. The UK National Institute of Health and Care 
Excellence (NICE) recommends the use of CKD–EPI for 
the majority of patients [67], but for the assessment of eGFR 
in those with CKD stage 3a (eGFR 45–59 mL/min/1.73  m2) 
and no proteinuria, the use of cystatin C-based equations 
is recommended [68]. Also the Kidney Disease Improving 
Global Outcomes (KDIGO), National Kidney foundation 
(NKF) and Caring for Australasians with Renal Impairment 
(CARI) guidelines recommend the use of CKD–EPI. The 
Cockroft–Gault algorithm may be the preferred option for 
the older population since this incorporates body size [69].
Cystatin C is a relatively new biomarker. Cystatin C based 
eGFR has been reported to correlate better with mortality 
risk factors in CKD patients than creatinine based eGFR [65, 
66]. Cystatin C is filtered by the glomerulus, is not secreted 
by the renal tubules and it is generated at a constant rate by 
all cells in the body [65, 66]. There are two formulae based 
on cystatin C; the CKD–EPI using cystatin C and CKD–EPI 
using a combination of cystatin C and creatinine [65, 66].
There are considerable differences in the resulting eGFR 
value and CKD classification [69] and accordingly, the 
choice of the method may have influenced the characteristics 
of patients included in studies.
Medication Use and Vitamin D
Many drugs used by CKD patients to manage symptoms of 
CKD and CVD influence vitamin D metabolism and synthe-
sis, although the mechanisms are still largely unknown [70]. 
The most commonly used therapies for CKD patients involve 
angiotensin inhibitors (ACE), aldosterone receptor antag-
onists (ARAs) and receptor blockers [70]. They are used 
to inhibit the RAAS [71]. Statins are also frequently used 
[72]. There are conflicting results on the association between 
these medications and vitamin D status. Yuste et al. found 
significant lower 25(OH)D levels in patients treated with 
statins compared to the patients treated with ACE inhibitors 
or ARAs [70]. In the same study they found higher 25(OH)
D levels in patient treated with xanthine oxidase inhibitors 
(medication for hyperuricemia) [70]. On the other hand, a 
different study showed no significant associations between 
concentrations of 25(OH)D and treatment with statins, ACE 
inhibitors and/or ARAs [73]. The use of these medications 
is however seldomly reported in RCTs.
Medication use or dietary strategies to manage hyper-
phosphatemia in CKD can also have influenced the findings 
and the reported side effects in these studies. Hyperphos-
phatemia is usually managed by dietary restriction of phos-
phate intake or prescription of phosphate binders [74] to 
decrease the availability of phosphate for intestinal absorp-
tion. There are three types of phosphate binders available: 
containing calcium, aluminum or non-calcium containing 
binders. Calcium based binders can be used as the initial 
binder therapy in CKD patients but are not the preferred 
option in case of hypercalcemia and/or when plasma PTH 
concentrations are < 150 pg/mL on two consecutive blood 
tests [75]. Calcimimetics are allosteric activators of the cal-
cium sensing receptor of parathyroidal cells [51]. Calcimi-
metics are usually prescribed in CKD patients with SHPT 
to activate calcium receptors and thus suppressing PTH [51] 
and are used when vitamin D analogues have failed to reduce 
SHPT. Calcimimetics in combination with active vitamin D 
therapy are used to reduce the risk of developing hypercal-
cemia and hyperphosphatemia [76].
A secondary analysis of a large study showed that the 
choice of phosphate binders may significantly impact vita-
min D metabolism and may influence the safety profile of 
vitamin D administration. In the Phosphate Normalization 
Trial on CKD patients [93], participants were randomized 
to receive either sevelamer carbonate, lanthanum carbon-
ate, calcium acetate for 9 months after which vitamin D 
metabolites were measured. In the group taking calcium 
acetate, 24,25(OH)2D, the vitamin D metabolite ratio 
(VMR) [24,25(OH)2D:25(OH)D] increased and 1,25(OH)2D 
decreased [77]. Also, the group taking sevelamer carbon-
ate had an increased 24,25(OH)2D and VMR, but this was 
lower than in the calcium acetate group [77]. No changes 
in 1,25(OH)2D were reported [77]. In the group taking 
lanthanum there we no changes in vitamin D metabolite 
concentrations.
In the studies included in this systematic review, patients 
were included that did or did not use phosphate binders and/
or calcimimetics. No clear pattern in the response or inci-
dence of hypercalcemia appeared amongst these studies.
Summary of Published Guidelines
Guidelines for Dietary Vitamin D Intakes 
and Supplementation for Population Health 
and Patient Management
General Population Requirements and Recommendations
Population guidelines for dietary vitamin D intakes are 
partly based on the required intakes to prevent vitamin D 
deficiency or to achieve pre-defined target ranges of 25(OH)
D or sufficiency. Also evidence from RCTs and other 
research designs linking vitamin D intake and status to 
health outcomes are considered. Thresholds for deficiency, 
i.e. the plasma concentration of 25(OH)D below which the 
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risk of disease increases, are predominantly defined on the 
basis of skeletal health outcomes, but in some guidelines 
also other health outcomes are considered. In most guide-
lines, minimal contribution of vitamin D synthesis in the 
skin is assumed. There is considerable variation in the defi-
nition and thresholds or ranges of 25(OH)D concentration 
that encompasses vitamin D sufficiency or target ranges of 
25(OH)D between health authorities. In addition, strate-
gies (e.g. type of data considered) to set requirements dif-
fer between health authorities. Review of approaches are 
beyond the scope of this review and are provided in Bouillon 
2017 [78].
Dietary reference values (DRV) or equivalents, defined 
by different public health institutes vary as a consequence of 
differences in the defined threshold for deficiency or target 
values for 25(OH)D and by age group or physiological state 
and are summarized in Table 3 [8, 79, 80]. The umbrella 
term DRV is used in Europe and World Health Organiza-
tion/Food and Agriculture Organization (WHO/FAO) and 
similarly, dietary reference intake (DRI) in the US. These 
comprise a range of nutrient values that apply to the general 
population or specific population groups [8, 79–81]. The 
DRV includes the Reference Nutrient Intake (RNI) which is 
the intake to meet the requirements of 97.5% of the popula-
tion. There where this cannot be established, an Adequate 
Fig. 2  Forest plots of the effect of different forms of vitamin D sup-
plementation on PTH concentrations in CKD patients. Top: a effect 
of vitamin  D2 or  D3 on PTH. Middle: b effect of calcitriol or ana-
logues on PTH. Bottom: c effect of calcitriol or analogues (active) 
versus Vitamin  D2 or  D3 (precursors) on PTH. PTH concentrations 
are given in pg/mL. Details on form and dosages are given in Table 1
Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and…
1 3
Intake (AI) is defined. Similarly in the US, the recommended 
dietary allowance (RDA) represents the requirements of 
97.5% of the population [82]. Population guidelines differ 
from clinical guidelines as the latter consider altered dietary 
requirements associated with underlying conditions.
Although vitamin D deficiency is one of the most com-
mon nutritional deficiencies in the world, no routine screen-
ing for the general population and most patient groups is rec-
ommended [9, 67, 81, 82]. Only people at high risk or with 
clinical features of vitamin D deficiency are recommended 
to be tested [83]. For example, KDIGO working group and 
NKF recommend annual screening for vitamin D deficiency 
for CKD patients [84]. CKD patients are classified as a high 
risk group due to their dietary modification (restricted pro-
tein intake), advice to restrict sunlight exposure and reduced 
cutaneous synthesis associated with common CKD comor-
bidities and renal losses.
Guidance for Patient Management and CKD Patients
Clinical guidelines for patient management or for specific 
patient groups provide guidance for the prevention and 
correction of vitamin D deficiency. These are partly based 
on population guidance or define specific target values for 
25(OH)D and vitamin D intakes, based on altered supply or 
bio-availability, metabolism and/or requirements. The UK 
NICE [67] and the US Endocrine Society [9] offer guide-
lines for prevention and treatment of vitamin D deficiency 
in patients, including CKD patients. The UK Royal Osteo-
porosis Society (ROS) [85] provides guidelines that focus 
on patients with osteoporosis and for osteomalacia and 
osteoporosis prevention (Table 4). Specific guidance for the 
management of CKD–MBD were developed by the NKF, 
the KDIGO CKD–MBD Guideline [84] and CARI [86–88]. 
Approaches and criteria used are discussed in more detail 
below.
The NKF and KDIGO guidelines cross-refer to guide-
lines for the general population, especially for patients in 
early stages of CKD. Specific guidelines for patients with 
advanced renal impairment include the use of vitamin D 
analogues [84]. These guidelines, including the daily rec-
ommended vitamin D intakes are detailed in Tables 5 and 
6 by CKD category. Additional recommendations are in 
place for patients with CKD 3–4. For these patients, it is 
recommended that with vitamin D supplementation, plasma 
calcium and phosphate should be monitored and supplemen-
tation dose should be adjusted when required [84] (Fig. 3).  
The US NKF developed the Kidney Disease Outcomes 
Quality Initiative (KDOQI), a specific CKD–MBD guide-
line (Clinical Practice Guidelines for Bone Metabolism and 
Disease in Chronic Kidney Disease), published in 2003 [75]. 
This guideline includes recommendations for the manage-
ment of vitamin D deficiency and SHPT, calcium and phos-
phate metabolism. Also the effects of vitamin D deficiency 
and supplementation on bone metabolism and disease were 
considered (Table 5). The guideline was predominantly 
based on evidence on the prevention and management of 
vitamin D deficiency and the progressive increase of PTH. It 
is acknowledged that there is a lack of high quality evidence 
for bone health or patient orientated clinical outcomes, 
such as mortality and cardiovascular disease risk. Part of 
this guidance was revised by NKF in 2016 [84] focusing 
on vitamin D deficiency and SHPT in CKD stages 3–4. In 
this updated guidance, targets for intact PTH thresholds 
by CKD category, as defined in the 2003 guideline were 
removed [84], due to lack of evidence of benefit. Specific 
Table 3  Population daily 
Reference Nutrient Intake 
(RNI) or Recommended 
Dietary Allowance (RDA) 
or equivalents for vitamin D 
according to different countries 
and organizations Ψ
After Lips et al. [79] and Bouillon [78]
*Adequate intake set for vitamin D intake based on target value of 25(OH)D; Ψ to convert from IU to μg 
divide by 40





Nordic countries [95] 400 (10) 400-800 (10–20) 25–30 nmol/L
UK [96] 400 (10) 400 (10) 25 nmol/L
Ireland [97] 0-400 (0–10) 400 (10) 30 nmol/L
Netherlands [98] 0-400 (0–10) 800 (20) 25–30 nmol/L
Belgium [98] 400-600 (10–15) 600 (15)
France [98] 200 (5) 400-600 (10–15)
DACH [98] 800 (20) 800 (20) 25–30 nmol/L
Spain [98] 600 (15) 600 (15)
Australia and New Zealand [86] 600 (15) 600-800 (15–20) 25–30 nmol/L
EFSA 2017 [81]* 600 (15) 600 (15) 50 nmol/L*
Institute of Medicine [82] 600 (15) 800 (20) 30 nmol/L
WHO/FAO 200 (5) 200 (5) 25 nmol/L
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dosage schemes for the prevention of vitamin D deficiency 
for CKD patients are not given in the NKF guidelines 2003 
[75] (Table 5), but for the correction of deficiency, recom-
mendations on dosages and duration are provided (Table 6). 
Vitamin D analogues are recommended only for patients 
with a progressive increase in PTH and for the treatment of 
SHPT. The 2016 update highlighted the potential benefits of 
the use of oral ER 25(OH)D in CKD patients. Few studies 
were available at that time to support this. In our systematic 
review, additional studies using this form of vitamin D are 
included. In 2017, a commentary was published, reflecting 
the views of the KDOQI CKD–MBD work group which 
were mostly in agreement with the updated KDIGO guide-
lines discussed below [89].
In 2003, the first detailed guidelines by KDIGO was pub-
lished [1]. In 2017 KDIGO issued their updated guideline 
for CKD–MBD [90] but little detail on the response to vita-
min D supplementation on PTH and bone turnover markers 
was included. In parallel to the NKF guideline, there are 
no specific recommendations (type of vitamin D, dose and 
duration) for the prevention of vitamin D deficiency and the 
treatment of SHPT due to a lack of sufficient high quality 
evidence specific to CKD patients. This guideline empha-
sizes the importance of managing other factors influencing 
PTH, including a high plasma phosphate and low calcium. 
This recommendation also considered reported adverse 
effects (since the previous review) of vitamin D analogues 
and calcitriol on the development of hypercalcemia, whilst 
clinically relevant outcomes did not substantially improve. It 
was therefore concluded that the risk–benefit ratio of treat-
ing an elevated PTH with these forms of vitamin D is no 
longer favourable for the majority of patients [75]. There-
fore, in this guideline, the use of vitamin D analogues and 
1,25(OH)2D are recommended only for patients with severe 
and progressive SHPT (Table 5).
The Kidney Health Australia, CARI guidelines of 
2012–2013 [86, 87] and the CKD guidelines for general 
practice issued in 2015 [88] recommend that vitamin D 
deficiency in CKD patients should be corrected following 
guidelines for the general population (Tables 3, 5). Vitamin 
D therapy on prescription is recommended for early stages 
of CKD with SHPT, with regular monitoring of plasma cal-
cium, phosphate, PTH, alkaline phosphatase and 25(OH)D. 
Treatment with 1,25(OH)2D is only recommended in later 
stages of CKD for the treatment of SHPT.
Thresholds and Correction of Vitamin D Deficiency
Thresholds for the definition of vitamin D deficiency for the 
general population differ between advisory bodies (summa-
rized in Table 3). Some, but not all, also provide thresholds 
of sufficiency. Recommended 25(OH)D target concentra-
tions and thresholds for deficiency for specific patient groups 
may be higher than for generally healthy people (Tables 4, 
6). Guidance for the correction of vitamin D deficiency is 
not provided in population guidance, but instead relies on 
country-specific clinical guidance for patient management. 
Tables 4 and 5 provides an overview of the recommenda-
tions from 4 authorities, including the NKF [9, 86].
There is considerable between-person variation in the 
dose–response to vitamin D because of the numerous fac-
tors that can affect plasma 25(OH)D and its increment after 
intake. Reported increases in plasma 25(OH)D in apparently 
healthy populations (including those that were deficient at 
baseline) range from 1.1 to 5.75 nmol/L per 100 IU/day 
[91–94]. This dose–response relationship is influenced by 
baseline concentrations of 25(OH)D, vitamin D dose, fre-
quency of administration, body composition and a number 
of medical conditions [47]. Population guidance for the pre-
vention of deficiency allows for these variations, but specific 
Table 4  Guidelines for the correction of vitamin D deficiency for patient management (general and for specific groups)
No specific guidelines for CKD patients are included. Endocrine society and ROS are led by clinical experts and NICE is a government led com-
mittee
Endocrine society [9] NICE [67] ROS [85]










Dietary intake for patients at risk: 19–70 year 
600 IU/day; > 70y 800 IU/day
Treating vitamin D deficiency in adults: 
50,000 IU/week for 8 weeks or 6000 IU/day
Followed by maintenance therapy of 1500–
2000 IU/day
Vitamin  D3 is the preferred form of supple-
mentation to treat vitamin D deficiency
Vitamin D deficiency treatment: Fixed loading 
dose of vitamin D up to total of 300,000 IU, 
split dose either weekly or daily
Followed by lifelong maintenance treatment of 
800 IU/day
Vitamin  D3 is recommended for treating vita-
min D deficiency
Vitamin D deficiency treatment: fixed loading 
up to a total of 300,000 IU given either as 
weekly or daily split doses
Maintenance therapy: started one month after 
loading with doses equivalent to 800–
2000 IU/day (maximum 4000 IU/day) given 
either daily or intermittently
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at risk groups may need higher intakes to prevent and cor-
rect vitamin D deficiency. For the correction of deficiency, 
higher intakes are required and often loading dosages are 
recommended, followed by maintenance therapy (Table 4). 
Clinical monitoring is required with these loading dosages.
Population guidance considered at what concentration 
range of 25(OH)D, the risk of SHPT was increased and this 
is incorporated in the assessment of vitamin D requirements 
[8, 82]. Also this relationship is characterized by a large 
variability and target values for PTH were not formulated 
for the general population.
In CKD patients, the threshold for vitamin D sufficiency 
and the vitamin D intake to achieve and maintain sufficiency 
is less well established than in generally healthy people. This 
partly due to the fact that few high quality studies relating 
25(OH)D with clinical outcomes, such as fragility fractures 
or bone mineral density, were conducted in CKD patients. 
Also, the heterogeneity in this patient group plays a role. In 
these patients, the vitamin D dose–response and relationship 
between 25(OH)D and PTH is dependent of CKD category, 
renal capacity to produce 1,25(OH)2D and the degree of 
PTH resistance. Also, diversity in clinical presentation of 
CKD–MBD, influences the response in bone metabolism.
For CKD patients, a higher target concentration 
(> 75 nmol/L) than for the general population is recom-
mended in the NKF and CARI guidelines [84, 86] with regu-
lar monitoring and correction as required on a 6–12 monthly 
basis (Tables 4, 5, 6 and Fig. 4). Target values for PTH could 
not be set on the basis of the evidence available. In addi-
tion, the PTH-25(OH)D relationship (used formulation of in 
many population guidelines) could not be used in the assess-
ment of vitamin D requirements for CKD patients due to 
their altered relationship. Current recommendations advise 
regular monitoring and management if PTH progressively 
increases. In view of the variability in clinical presentation, 
patients are managed on a case-by-case basis with monitor-
ing of calcium and phosphate homeostasis (Fig. 4).
Guidance for management of vitamin D status and defi-
ciency, population recommendations and patient manage-
ment are summarized in Tables 3, 4 and Fig. 4.
Conclusion
Major gaps remain in the evidence base for the manage-
ment of vitamin D status in relation to CKD–MBD, i.e. the 
dose–response, SHPT, altered bone metabolism, bone den-
sity and integrity and fracture risk. Recent studies included 
in this systematic review varied in design, vitamin D form 
used there was a high degree of heterogeneity with regard 
to duration, dose, and population characteristics. Our sys-
tematic review showed that the effect of vitamin D on PTH 
concentrations was inconsistent between studies and meta-
analyses showed a non-significant reduction. This is in 
contrast to findings in studies in patients not selected on 
basis of pre-existing CKD. This is likely explained by the 
small sample size of studies and the fact that in some but 
not all patients with CKD, other drivers are predominant 
and prevent a decrease of PTH secretion. More consistent 
effects on PTH was found with calcifediol; all 4 studies 
that used this form reported a reduced PTH. Also treat-
ment with calcitriol and paricalcitol was associated with 
a consistent suppression of PTH. An increase Fibroblast 
Growth Factor 23 (FGF23) after treatment with vitamin 
D analogues was observed in all 3 studies reporting this 
outcome, but was unaltered in 4 studies with Vitamin D or 
25(OH)D. The increase in FGF23 with analogue admin-
istration warrants attention as this hormone is already 
elevated in CKD patients and is a predictor of vascular cal-
cification and CVD. It’s increase may indicate an undesir-
able side effect of administration of these forms of vitamin 
Table 6  Guidelines correction and monitoring of vitamin D deficiency in patients with CKD 3 and 4
After NKF KDOQI (2003): Guideline 7;Table 26 [75]
Serum 25(OH)D nmol/L
[ng/mL]
Definition Vitamin  D2 dose Duration (months) Comment
< 12 [< 5] Severe vitamin D deficiency 50,000 IU/w orally × 12 weeks; 
then monthly
6 months Measure 25(OH)D levels after 
6 months
500,000 IU as a single I.M. 
dose
n/a Assure patient adherence; 
measure 25(OH)D at 
6 months
12–37 [5–15] Mild vitamin D deficiency 50,000 IU/w × 4 weeks; then 50 
000 IU/m orally
6 months Measure 25(OH)D levels after 
6 months
40–75 [16–29] Vitamin D insufficiency 50,000 IU/m orally 6 months n/a
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D. Few RCTs reported the effect of vitamin D on markers 
of bone metabolism and variations in the range of markers 
prevented direct comparisons. However, all 4 studies that 
measured either ALP or BALP after paricalcitol treatment 
reported a decrease in this marker that is indicative of 
increased bone turnover in CKD patients.
Guidelines for the first stages (G1–G3a) follow general 
population recommendations for the prevention of vitamin 
D deficiency. For the correction of deficiency, general or 
CKD specific patient guidelines provide recommendations. 
These are summarized in a tabulated format to facilitate 
their use in clinical practice.
Fig. 3  Changes in Vitamin D 
metabolism and the renal-bone 
axis with CKD. Arrows indicate 
direction of changes with CKD. 
With chronic kidney disease the 
combination of limited vitamin 
D intake and reduced renal 
capacity to activate 25(OH)D to 
1,25(OH)2D results to a chain 
reaction of changes in metabo-
lism. A decrease in 1,25(OH)2D 
results in a decrease in intestinal 
absorption of calcium. This 
stimulates PTH secretion which 
in turn increases bone resorp-
tion. Phosphate retention due 
to reduced kidney filtration 
capacity further stimulates 
PTH and the production and 
release of FGF23 from bone 
cells to increase renal phosphate 
excretion




Is serum 25(OH)D 
<75nmol/L





Monitor serum Ca 
and P every 3 months
Is serum Ca 
<10.2 mg/dl?
Hold vitamin D 
supplementation
Is serum P 
<4.6 mg/dl?
Restrict dietary phosphate/ 
Initiate or increase 
phosphate binders
Is serum PTH within 
the normal or upper 
limit of the assay?
Continue or resume 
vitamin D2 or D3
supplementation
Summary of RCT outcomes
Paricalcitol or 1,25(OH)2D: ↑↔ 
25(OH)D, ↓ PTH, ↓ALP, ↑FGF23, ↑↔ 
calcium,  ↑↔phosphate
Summary of RCT outcomes
Vitamin D3 or D2: ↑ 25(OH)D, ↓↔ 
PTH, ↔ calcium, ↔ phosphate
25(OH)D: ↑ 25(OH)D, ↑ 
1,25(OH)2D, ↔ P, ↓PTH, only 1 
RCT available
ER 25(OH)D ↔↑ 25(OH)D ↓ PTH, 
↑ 25(OH)D, ↔ 24,25(OH)2D, ↔ 







Is serum PTH 
persistent and 
progressive over upper 





Fig. 4  Guidance for monitoring of vitamin D status and supplementa-
tion and monitoring of calcium and phosphate metabolism in CKD 
stages G3–4. Based on recommendations from the different organi-
zations summarized in Table 5. Adapted from: NKF KDOQI (2003) 
[75]. Finding in recent RCTs (2003–2020) included in the system-
atic review are summarized in yellow boxes. For abbreviations see 
Table 1
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